D05 Overzicht aandelen A biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Leg je gedachten, links en bedrijfsverhaal vast
Deciphera Pharmaceuticals, Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Deciphera Pharmaceuticals Historische aandelenkoersen Huidige aandelenkoers US$23.60 52 Week Hoogtepunt US$23.80 52 Week Laag US$9.51 Bèta 0.18 1 maand verandering 0% 3 maanden verandering 60.49% 1 Jaar Verandering 84.66% 3 jaar verandering -19.18% 5 jaar verandering 11.58% Verandering sinds IPO 40.22%
Recent nieuws en updates
Deciphera Pharmaceuticals, Inc. Files Form 15 Jun 22 Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet Jun 05
First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023) May 11 Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion. Apr 30
Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 27 Meer updates bekijken
Deciphera Pharmaceuticals, Inc. Files Form 15 Jun 22 Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet Jun 05
First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023) May 11 Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion. Apr 30
Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 27
Full year 2023 earnings released: US$2.29 loss per share (vs US$2.37 loss in FY 2022) Feb 07
Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024 Feb 02
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 Jan 09
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Jan 05
President recently sold €437k worth of stock Dec 17
Senior VP & Chief Commercial Officer recently sold €205k worth of stock Dec 04
President recently sold €244k worth of stock Nov 02
President recently sold €244k worth of stock Nov 02
Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Oct 31
Third quarter 2023 earnings released: US$0.58 loss per share (vs US$0.55 loss in 3Q 2022) Oct 31
New minor risk - Share price stability Oct 10
Second quarter 2023 earnings released: US$0.57 loss per share (vs US$0.60 loss in 2Q 2022) Aug 10
Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023 Aug 05
Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
Now 22% undervalued after recent price drop Jun 15
Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting May 26
Now 22% undervalued after recent price drop May 23
Independent Director recently bought €139k worth of stock May 15
First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.80 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$2.37 loss per share (vs US$5.16 loss in FY 2021) Feb 08
Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023 Feb 01
Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Jan 25
Now 21% undervalued Jan 11
Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022 Jan 05 Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.37 loss in 3Q 2021) Nov 04
Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022 Sep 12
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022 Sep 11
Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology Aug 11
Second quarter 2022 earnings released: US$0.60 loss per share (vs US$1.22 loss in 2Q 2021) Aug 05
Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer Jun 17
First quarter 2022 earnings released: US$0.80 loss per share (vs US$1.06 loss in 1Q 2021) May 05
Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022 May 03
Insufficient new directors Apr 27
Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting Apr 13
Insufficient new directors Mar 02
Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022 Feb 02
Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Jan 25
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Dec 22
Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor Nov 24
Third quarter 2021 earnings released: US$1.37 loss per share (vs US$1.13 loss in 3Q 2020) Nov 03
Executive VP & Chief Medical Officer recently sold €76k worth of stock Oct 09 Deciphera Pharmaceuticals, Inc. Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Second quarter 2021 earnings released: US$1.22 loss per share (vs US$1.20 loss in 2Q 2020) Aug 05
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene Jul 01
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Jun 05
First quarter 2021 earnings released: US$1.06 loss per share (vs US$1.36 loss in 1Q 2020) May 06
New 90-day low: €34.40 Feb 27
Full year 2020 earnings released: US$4.78 loss per share (vs US$4.49 loss in FY 2019) Feb 11
Revenue beats expectations Feb 11
Deciphera Pharmaceuticals, Inc. Announces Appointment of Margarida Duarte as Senior Vice President, Head of International Feb 10
Deciphera Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 09, 2021 Feb 03
New 90-day low: €38.20 Jan 23
New 90-day low: €43.00 Jan 07
Deciphera Pharmaceuticals, Inc. Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor Dec 01
New 90-day high: €54.50 Nov 13 Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
Revenue beats expectations Nov 07
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize Qinlock (Ripretinib) Nov 07
Specialised Therapeutics Asia Signs an Agreement with Deciphera Pharmaceuticals, Inc. to Commercialise the Switch-Control Tyrosine Kinase Inhibitor QINLOCK (ripretinib) Nov 06
Deciphera Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 29
New 90-day high: €52.50 Oct 24
New 90-day high: €48.20 Oct 08
Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology Virtual Congress 2020 Sep 19
Deciphera Pharmaceuticals, Inc. Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Sep 18
New 90-day low - €36.80 Aug 20
Deciphera Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 04, 2020 Jul 31
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from Russell Microcap Index Jul 02 Rendement voor aandeelhouders D05 DE Biotechs DE Markt 7D 1.7% 1.2% 2.3% 1Y 84.7% -5.6% 16.7%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: D05 overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -5.6 % opleverde.
Rendement versus markt: D05 overtrof de German markt, die het afgelopen jaar een rendement opleverde van 16.7 %.
Prijsvolatiliteit Is D05's price volatile compared to industry and market? D05 volatility D05 Average Weekly Movement 22.0% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stabiele aandelenkoers: De aandelenkoers van D05 is de afgelopen 3 maanden volatiel geweest in vergelijking met de German markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van D05 is het afgelopen jaar gestegen van 12% naar 22%.
Over het bedrijf Meer tonen Deciphera Pharmaceuticals, Inc. Samenvatting Hoe verhouden de winst en inkomsten van Deciphera Pharmaceuticals zich tot de beurswaarde? D05 fundamentele statistieken Marktkapitalisatie €2.06b Inkomsten(TTM ) -€177.33m Inkomsten(TTM ) €162.89m
12.7x P/S-verhouding
-11.6x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) D05 resultatenrekening (TTM ) Inkomsten US$174.91m Kosten van inkomsten US$242.52m Brutowinst -US$67.61m Overige uitgaven US$122.80m Inkomsten -US$190.42m
Laatst gerapporteerde inkomsten
Mar 31, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -2.20 Brutomarge -38.66% Nettowinstmarge -108.87% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde D05 op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/06/11 23:08 Aandelenkoers aan het einde van de dag 2024/06/11 00:00 Inkomsten 2024/03/31 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie .
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github .
Bronnen van analisten Deciphera Pharmaceuticals, Inc. wordt gevolgd door 17 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Madhu Kumar B. Riley Securities, Inc. Arlinda Lee Canaccord Genuity Charles Duncan Cantor Fitzgerald & Co.
Toon 14 meer analisten 
